Gan&Lee Pharmaceuticals stated on November 26 in response to investor inquiries that its business operations remain normal. In the first three quarters of 2025, the company reported revenue of 3.047 billion yuan, an increase of 802 million yuan year-on-year, representing a growth of 35.73% compared to the same period last year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments